TCL Archive EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation May 30, 2014
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
